Rani Therapeutics Holdings, Inc.

RANI

US7530181004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.56 ^USD	-6.15%		+8.43%	+97.59%

Mar. 27	Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	MT
Mar. 25	HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	MT

Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) added to S&P Global BMI Index

December 20, 2021 at 12:00 am EST

Latest news about Rani Therapeutics Holdings, Inc.

Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	Mar. 27	MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	Mar. 25	MT
Transcript : Rani Therapeutics Holdings, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
Transcript : Rani Therapeutics Holdings, Inc. - Special Call	Feb. 05
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)	Feb. 05	CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope	Dec. 14	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 01	MT
Sector Update: Health Care	Dec. 01	MT
Rani Therapeutics Stock Climbs After Share Purchase by CEO	Dec. 01	MT
Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating	Nov. 10	MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating	Nov. 09	MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform	Nov. 01	CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration	23-10-25	CI
Rani Therapeutics Reports 'Successful' Oral Delivery of Humira in High-Capacity Pill in Preclinical Study	23-10-19	MT
Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study	23-10-19	CI
Sector Update: Health Care Stocks Mixed Premarket Monday	23-09-18	MT
Rani Therapeutics Starts Early Stage Trial of Autoimmune Disease Treatment Candidate	23-09-18	MT
Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)	23-09-18	CI
Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) dropped from S&P Global BMI Index	23-09-18	CI
Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies	23-09-07	CI
HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating	23-08-14	MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI

Chart Rani Therapeutics Holdings, Inc.

Duration

Period

More charts

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.56 USD

Average target price

8.857 USD

Spread / Average Target

+35.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RANI THERAPEUTICS HOLDINGS, INC.	+97.59%	173M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-11.11%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs